Literature DB >> 20802486

Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance.

Alexandre Wohlkonig1, Pan F Chan, Andrew P Fosberry, Paul Homes, Jianzhong Huang, Michael Kranz, Vaughan R Leydon, Timothy J Miles, Neil D Pearson, Rajika L Perera, Anthony J Shillings, Michael N Gwynn, Benjamin D Bax.   

Abstract

Quinolone antibacterials have been used to treat bacterial infections for over 40 years. A crystal structure of moxifloxacin in complex with Acinetobacter baumannii topoisomerase IV now shows the wedge-shaped quinolone stacking between base pairs at the DNA cleavage site and binding conserved residues in the DNA cleavage domain through chelation of a noncatalytic magnesium ion. This provides a molecular basis for the quinolone inhibition mechanism, resistance mutations and invariant quinolone antibacterial structural features.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20802486     DOI： 10.1038/nsmb.1892

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN： 1545-9985            Impact factor:   15.369


  10 in total

Review 1.  Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents.

Authors:  Lester A Mitscher
Journal:  Chem Rev       Date:  2005-02       Impact factor: 60.622

Review 2.  Drugs for bad bugs: confronting the challenges of antibacterial discovery.

Authors:  David J Payne; Michael N Gwynn; David J Holmes; David L Pompliano
Journal:  Nat Rev Drug Discov       Date:  2006-12-08       Impact factor: 84.694

3.  Structural basis for gate-DNA recognition and bending by type IIA topoisomerases.

Authors:  Ken C Dong; James M Berger
Journal:  Nature       Date:  2007-12-20       Impact factor: 49.962

4.  Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases.

Authors:  Ivan Laponogov; Maninder K Sohi; Dennis A Veselkov; Xiao-Su Pan; Ritica Sawhney; Andrew W Thompson; Katherine E McAuley; L Mark Fisher; Mark R Sanderson
Journal:  Nat Struct Mol Biol       Date:  2009-05-17       Impact factor: 15.369

Review 5.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; John S Bradley; John E Edwards; David Gilbert; Louis B Rice; Michael Scheld; Brad Spellberg; John Bartlett
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

6.  X-Ray crystallographic, NMR and antimicrobial activity studies of magnesium complexes of fluoroquinolones - racemic ofloxacin and its S-form, levofloxacin.

Authors:  Petra Drevensek; Janez Kosmrlj; Gerald Giester; Tormod Skauge; Einar Sletten; Kristina Sepcić; Iztok Turel
Journal:  J Inorg Biochem       Date:  2006-07-04       Impact factor: 4.155

7.  Ciprofloxacin affects conformational equilibria of DNA gyrase A in the presence of magnesium ions.

Authors:  C Sissi; E Perdonà; E Domenici; A Feriani; A J Howells; A Maxwell; M Palumbo
Journal:  J Mol Biol       Date:  2001-08-03       Impact factor: 5.469

8.  Performance of detecting IgM antibodies against enterovirus 71 for early diagnosis.

Authors:  Feihai Xu; Qiang Yan; Hua Wang; Jianjun Niu; Liang Li; Fengcai Zhu; Shuizhen He; Shiyin Zhang; Zuxing Weng; Tong Cheng; Yijun Cai; Delei He; Yixin Chen; Shengxiang Ge; Anthony E T Yeo; Jun Zhang; Mun-Hon Ng; Ningshao Xia
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

9.  Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli.

Authors:  H Yoshida; M Bogaki; M Nakamura; L M Yamanaka; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

10.  Hot-spot consensus of fluoroquinolone-mediated DNA cleavage by Gram-negative and Gram-positive type II DNA topoisomerases.

Authors:  Sara N Richter; Giulia Giaretta; Valentina Comuzzi; Elisabetta Leo; Lesley A Mitchenall; L Mark Fisher; Anthony Maxwell; Manlio Palumbo
Journal:  Nucleic Acids Res       Date:  2007-08-30       Impact factor: 16.971
  10 in total
  96 in total

1.  Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.

Authors:  Katie J Aldred; Sylvia A McPherson; Pengfei Wang; Robert J Kerns; David E Graves; Charles L Turnbough; Neil Osheroff
Journal:  Biochemistry       Date:  2011-12-16       Impact factor: 3.162

Review 2.  Understanding the structural mechanisms of antibiotic resistance sets the platform for new discovery.

Authors:  Stephanie M Reeve; Michael N Lombardo; Amy C Anderson
Journal:  Future Microbiol       Date:  2015-10-30       Impact factor: 3.165

3.  First ruthenium organometallic complex of antibacterial agent ofloxacin. Crystal structure and interactions with DNA.

Authors:  Iztok Turel; Jakob Kljun; Franc Perdih; Elena Morozova; Vladimir Bakulev; Nina Kasyanenko; Jo Ann W Byl; Neil Osheroff
Journal:  Inorg Chem       Date:  2010-10-26       Impact factor: 5.165

4.  Resistance and Virulence Mechanisms of Escherichia coli Selected by Enrofloxacin in Chicken.

Authors:  Jun Li; Haihong Hao; Menghong Dai; Heying Zhang; Jianan Ning; Guyue Cheng; Muhammad Abu Bakr Shabbir; Abdul Sajid; Zonghui Yuan
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

5.  Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.

Authors:  Katie J Aldred; Heidi A Schwanz; Gangqin Li; Sylvia A McPherson; Charles L Turnbough; Robert J Kerns; Neil Osheroff
Journal:  ACS Chem Biol       Date:  2013-09-30       Impact factor: 5.100

6.  Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.

Authors:  Elizabeth G Gibson; Alexandria A Oviatt; Monica Cacho; Keir C Neuman; Pan F Chan; Neil Osheroff
Journal:  Biochemistry       Date:  2019-10-28       Impact factor: 3.162

7.  Rapid Evolution of Reduced Susceptibility against a Balanced Dual-Targeting Antibiotic through Stepping-Stone Mutations.

Authors:  Petra Szili; Gábor Draskovits; Tamás Révész; Ferenc Bogár; Dávid Balogh; Tamás Martinek; Lejla Daruka; Réka Spohn; Bálint Márk Vásárhelyi; Márton Czikkely; Bálint Kintses; Gábor Grézal; Györgyi Ferenc; Csaba Pál; Ákos Nyerges
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

8.  The C7-aminomethylpyrrolidine group rescues the activity of a thio-fluoroquinolone.

Authors:  Sarah R C Lentz; Pratik R Chheda; Lisa M Oppegard; Tyrell R Towle; Robert J Kerns; Hiroshi Hiasa
Journal:  Biochimie       Date:  2019-02-11       Impact factor: 4.079

9.  The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage.

Authors:  Timothy J Wendorff; Bryan H Schmidt; Pauline Heslop; Caroline A Austin; James M Berger
Journal:  J Mol Biol       Date:  2012-07-25       Impact factor: 5.469

Review 10.  Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance.

Authors:  David C Hooper; George A Jacoby
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.